Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT03172624
- Phase
- PHASE2
- Status
- Completed
Conditions
- Salivary Gland Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — DRUGnivolumab 3 mg/kg every 2 weeks
- Ipilimumab — DRUGipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
Study Details
The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.
Key Dates
- Start date
- May 26, 2017
- Status verified
- Dec 2024
- Primary completion
- Dec 18, 2024
- Completion
- Dec 18, 2024
Study Design
- Enrollment
- 64 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: R/M adenoid cystic carcinoma (ACC)Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
- Experimental: R/M SGC of any histology, except ACC (Non ACC)Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
Primary Outcome Measure
Best Overall Response Rate [ Time Frame: 2 years ]
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | 07920 | - |
| Memorial Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | - |
| Memorial Sloan Kettering Bergen | Montvale | New Jersey | 07645 | - |
| Memorial Sloan Kettering Commack | Commack | New York | 11725 | - |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
| Memorial Sloan Kettering Rockville Centre | Rockville Centre | New York | 11570 | - |
| Memorial Sloan Kettering Nassau | Uniondale | New York | 11553 | - |
Related coverage on Hipa.ai
- Nivolumab Plus Ipilimumab Shows Responses in Salivary Gland Cancer TrialNivolumab · Dec 18, 2025 · ClinicalTrials.gov
Find similar trials in Basking Ridge, NJ
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasPHASE2 · Recruiting · Dana-Farber Cancer Institute · Atlanta, Georgia
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPHASE2 · Recruiting · Jazz Pharmaceuticals · Prescott, Arizona
- Drug Screening Using Novel IMD in Salivary and Head and Neck CancersEARLY_PHASE1 · Recruiting · Brigham and Women's Hospital · Boston, Massachusetts